Format

Send to

Choose Destination
J Atten Disord. 2017 Feb;21(4):343-352. doi: 10.1177/1087054714538656. Epub 2016 Jul 28.

Memantine in the Treatment of Executive Function Deficits in Adults With ADHD.

Author information

1
1 Massachusetts General Hospital, Boston, MA, USA.
2
2 State University of New York Upstate Medical University, Syracuse, MA, USA.

Abstract

OBJECTIVE:

To evaluate the efficacy and safety of memantine hydrochloride as an adjunct to stimulant pharmacotherapy for treating executive function deficits (EFDs) in adults with ADHD.

METHOD:

This was a 12-week, double-blind, placebo-controlled, randomized clinical trial of memantine added to open-label treatment with stimulant medication. Because of the small sample size, we considered a standardized mean difference (equivalent to effect size) of ≥0.5 and odds ratios ≥2 as indicators of trend improvements.

RESULTS:

Twelve participants received memantine and 14 received a placebo. Trend improvements favoring memantine were observed on Behavior Rating Inventory of Executive Functions-Adult Inhibition and Self-Monitor subscales when compared with Placebo. No significant changes were noted on the Cambridge Neuropsychological Test Automated Battery.

CONCLUSION:

Among adults with ADHD and EFDs, adjunct treatment with memantine to osmotic release oral system-methylphenidate (OROS-MPH) was associated with improvements in selective areas of executive functioning, supporting the need for further research.

KEYWORDS:

ADHD; adult; adult ADHD treatment; executive function deficits; memantine

PMID:
24970718
DOI:
10.1177/1087054714538656
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Atypon
Loading ...
Support Center